PROPOSED MERGER BETWEEN CLICKS RETAILERS (PTY) LTD AND NETCARE PHARMACIES (PTY) LTD AND NETCARE PHARMACIES 2 (PTY) LTD 2016Jun0297
|
|
- Noreen King
- 5 years ago
- Views:
Transcription
1 ICPA (NPC), Unit 3, Mews 2, Rosmead Centre, 67 Rosmead Avenue, Kenilworth, Cape Town, 7708 Tel: Fax: Website: CIPC Reg. No: 2012/021809/08 NPO Reg. No: VAT Reg. No: August 2016 Portia Bele Mergers and Acquisitions Competition Commission SA By PortiaB@compcom.co.za Dear Ms. Bele, PROPOSED MERGER BETWEEN CLICKS RETAILERS (PTY) LTD AND NETCARE PHARMACIES (PTY) LTD AND NETCARE PHARMACIES 2 (PTY) LTD 2016Jun We refer to the telephone conversation and following correspondence between your Portia Bele and our Mark Payne on 28 July As mentioned in the above previous correspondence, the Independent Community Pharmacy Association ( ICPA ) is an organisation which provides independent community pharmacies with collective strength in their dealings with government, medical schemes, pharmaceutical suppliers and consumers. 3. ICPA represents over independent pharmacies amounting to roughly pharmacists and supportive healthcare personnel. ICPA s objective is to assist and support its members in securing a sustainable and successful future as independent owner-managed pharmacies. 4. The supply of medicines is regulated with legislative parameters set out for the single exit price of medicine and the dispensing fee that may be charged by pharmacies and which limits the profitability of pharmacies. 5. ICPA has concerns regarding the proposed merger between the abovementioned parties which is to be discussed under the following headings: Board of Directors: Mogologolo Phasha (Chairman), Wim Grobbelaar (Vice-Chairman), Mehboob Ali Cassim (Treasurer), Rakesh Daya, Maropeng Modiba, Sham Moodley, Simoné Eksteen
2 5.1 Transgression of the Pharmacy Act by Clicks Retailers (Pty) Ltd It is prohibited for an owner of a retail (community) pharmacy (like the current Medicross pharmacies and Clicks pharmacies) to have a direct or indirect beneficial interest in a manufacturing pharmacy Clicks Group Limited (trading under registration number 1996/000645/06) is the holding company of Clicks Retailers (Pty) Ltd ( Clicks ), trading under registration number 2000/013054/07, and Unicorn Pharmaceuticals (Pty) Ltd ( Unicorn ), trading under registration number 2000/017879/ On 30 May 2012 Unicorn was issued with a manufacturing licence. As it is prohibited for the owner of a community pharmacy to have a direct or indirect beneficial interest in a manufacturing pharmacy, all licences issued subsequent to 30 May 2012 were erroneously issued and should be revoked. This issue was raised in our submissions made to the Competition Commission Health Market Inquiry in February 2016 and a formal complaint was also lodged with the Department of Health (attached hereto as Annexure 1), who referred it to their legal department for investigation Should this merger proceed all the Clicks pharmacies that will take over control from the Medicross pharmacies will have to apply for new community pharmacy licences in order to proceed conducting business as community pharmacies. Should these licences be granted, they will be conducting business in contravention of the Pharmacy Act and we will be obliged to approach the courts to interdict them from conducting business in contravention with the law. We appreciate that this issue should be raised with the Department of Health, but we have done so and is yet to receive any resolve in this regard. We submit, however, that this should be taken into account by the Competition Commission before awarding them permission to proceed with this merger. 5.2 Vertical integration Clicks have vertically integrated their pharmaceutical supply chain in that the distributor, wholesaler and retailer are all subsidiaries of Clicks Group Limited. 1 In terms of section 22A of the Pharmacy Act, Act 53 of 1974, read together with Regulation 6 of the Regulations relating to the Ownership and Licensing of Pharmacies, dated 21 February
3 5.2.2 As a result hereof profit can be generated at different levels of the supply chain and losses can also be absorbed at different levels. This, together with their negotiating power as a corporate pharmacy, to be discussed below, allows them to contract with medical aid schemes at lower dispensing fee rates. This, in turn, results in medical aid schemes contracting Clicks pharmacies as the designated service provider ( DSP ) for chronic medicine denying the medical aid scheme members choice of service provider and forcing them to use the DSP or face a hefty penalty co-payment Understandably this does not necessarily constitute vertical restrictive practices as to our understanding Clicks and Unicorn can be viewed as a single economic entity, but because of the highly regulated end to end medicine supply chain, privately owned pharmacies are unable to compete as a result of these factors. 5.3 Negotiating power of corporate pharmacy as opposed to independent pharmacies As mentioned above the medicine supply chain is heavily regulated and innovative business models are required for a retail pharmacy to maintain profitability A restriction on independent pharmacies is the fact that they are barred from collectively negotiating dispensing fee rates with medical aid schemes as well as forming joint purchasing arrangements with manufacturers and wholesalers, as this may be regarded as price fixing. We attach hereto as Annexure 2 the advisory letter from the Competition Commission in this regard This restriction is not applicable to corporate pharmacy (and thus to Clicks pharmacies). Clicks therefore has more negotiation power to negotiate dispensing fee rates with medical aid schemes and may purchase unregulated predominantly front shop items in bulk enabling them to sell it at a lower price. This, again, makes it impossible for independent pharmacies to compete. 5.4 Transgression of the Medicines and Related Substances Act, Act 101 of 1965 ( Medicines Act ) It is illegal for a person to supply any medicine according to a bonus system, rebate system or any other incentive scheme. 2 2 In terms of section 18A of the Medicines Act. 3
4 5.4.2 Clicks, under the Healthycare benefit to Discovery Vitality members, acts unlawfully by offering rebates classified as incentives on medicines regulated by a single exit price. This contravention of the Medicines Act gives Clicks a competitive advantage above independent community pharmacies who once again lose out on successfully competing with corporate pharmacy. 5.5 Dominance in the market and exclusivity of Unicorn products ICPA is not in a position to make submissions based on economic analysis on Clicks market share and market power, but trusts that the Competition Commission will evaluate same to establish if Clicks is indeed a dominant firm or not In the event of the Competition Commission finding that Clicks has enough market power to establish itself as a dominant firm, then it can be argued that there is an abuse of market dominance in that Unicorn products are only made available to Clicks pharmacies and to a lesser degree Link pharmacies (who is also affiliated with Clicks Group Limited). Independent pharmacies are precluded from procuring products from Unicorn, despite some of these products being on medical aid scheme formularies. This seems to be a transgression of section 8(d)(i) the Competition Act Annexure J to Annexure 1 hereto indicates the Clicks private conversion tool, supposedly advising Clicks personnel which products compete with their branded range and the equivalent Clicks private label product to be marketed to customers. The logical assumption is that Clicks pharmacists are incentivised for selling Clicks (Unicorn) products, despite it perhaps not being the best indicated medicine. If this is indeed the case, it can also resort under the same transgression of section 8(d)(i) of the Competition Act and can lead to serious harm to consumer welfare. ICPA again trusts that the Competition Commission will investigate the possible abuse of dominance by Clicks The fact that Clicks has a beneficial interest in the manufacturer of medicines marketed in pharmacies may lead to perverse incentives. The consumer s choice is being swayed to Unicorn products, as opposed to a variety of products from different pharmaceutical manufacturers as the case would be in a community pharmacy. 4
5 5.6 Compliance to the Pharmacy Act, its regulations and the Rules to Good Pharmacy Practice Pharmacy premises situated within another business must be clearly identified and demarcated from the premises of any other business or practice The pharmacies situated in the Netcare hospitals have institutional pharmacy licences and those situated in Medicross have community pharmacy licences. The biggest distinction between the two is that institutional pharmacies may not provide pharmaceutical services to the general public, but only to in-patients of the facility 4. The proposed Netcare front shop operations to be taken over by Clicks will only be at liberty to sell unscheduled medicine and other unregulated products located in the front shop. The above will require monitoring to ensure compliance with the Pharmacy Act. Should the proposed merger proceed, the market share and market power of Clicks will increase in a market that is already difficult for independent pharmacies to compete. We have indicated in the aforementioned that Clicks continues to transgress the relevant legislation and this affects the ability of small and medium enterprises to compete on equal footing. On these ground we hereby request the Competition Commission not to grant approval for the merger. Regards, INDEPENDENT COMMUNITY PHARMACY ASSOCIATION Per: Mogologolo David Phasha Chairman 3 In terms of Rule (a) of the Rules relating to Good Pharmacy Practice. 4 In terms of the 2003 Regulations relating to Ownership and Licensing of Pharmacies of the Pharmacy Act. 5
Reasons for Decision
-- ----- -----! ---~-------------- -------- con-1pc-i itiontribunal '"" 'f, 'fr i,.., COMPETITION TRIBUNAL OF SOUTH AFRICA In the matter between: Case No: LM055Jul16 Clicks Retailers (Pty) Ltd Primary
More informationSHPA Response to Consultation on the Community Service Obligation (CSO) Funding Pool Obligations (2018)
SHPA Response to Consultation on the Community Service Obligation (CSO) Funding Pool Obligations (2018) The Society of Hospital Pharmacists of Australia (SHPA) is the national professional organisation
More informationPBM MODEL A A MODEL ACT RELATING TO PHARMACY BENEFIT MANAGERS*
PBM MODEL A A MODEL ACT RELATING TO PHARMACY BENEFIT MANAGERS* Whereas: It is essential to understand the drivers and impacts of prescription drug costs, and transparency is the first step toward that
More informationIN THE CIRCUIT COURT OF MONTGOMERY COUNTY, ALABAMA ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )
IN THE CIRCUIT COURT OF MONTGOMERY COUNTY, ALABAMA MEDFUSIONRX, LLC v. Plaintiff, DAVID BRONNER, in his official capacity as Secretary-Treasurer and Chief Executive Officer of RSA, DR. PAUL R. HUBBERT,
More informationOrder. Further to the application of the Competition Commission in terms of Section 49D, in the above matter-
COMPETITION TRIBUNAL REPUBLIC OF SOUTH AFRICA Case No: 89/CR/Nov04 In the matter between: The Competition Commission Applicant and J Melnick & Co (Pty) Ltd Respondent Order Further to the application of
More informationFrequently Asked Questions (FAQs) About the LIPITOR Savings Program*
Frequently Asked Questions (FAQs) About the LIPITOR Savings Program* *Terms and conditions apply. Please see page 9 for details. You may pay less by receiving the generic. Below are some FAQs about the
More informationGuide to Prescribed Minimum Benefits 2018
Guide to Prescribed Minimum Benefits 2018 Who we are Remedi Medical Aid Scheme (referred to as 'the Scheme"), registration number 1430, is a non-profit organisation, registered with the Council for Medical
More informationPublic Participation: LLA Liquor Licence Application - Require your feedback
Thornton RPA Public Participation: LLA1806020 Liquor Licence Application - Require your feedback Subcouncil 15 Fri, Jun 22, 2018 at 8:42 AM To: Brian
More informationIn electronic form on the EUR-Lex website under document number 32016M7818
EN EUROPEAN COMMISSION DG Competition Case M.7818 - MCKESSON / UDG HEALTHCARE (PHARMACEUTICAL WHOLESALE AND ASSOCIATED BUSINESSES) Only the English text is available and authentic. REGULATION (EC) No 139/2004
More informationApril 8, Dear Mr. Levinson,
April 8, 2019 Daniel Levinson Office of Inspector General Department for Health and Human Services Cohen Building, Room 5527 330 Independence Ave, SW Washington, DC 20201 Re: Fraud and Abuse; Removal of
More informationSTATE OF NEW JERSEY. SENATE, No th LEGISLATURE. Sponsored by: Senator NIA H. GILL District 34 (Essex and Passaic)
SENATE, No. STATE OF NEW JERSEY th LEGISLATURE INTRODUCED FEBRUARY, 00 Sponsored by: Senator NIA H. GILL District (Essex and Passaic) SYNOPSIS Regulates pharmacy benefits management companies. CURRENT
More informationGuide to Prescribed Minimum Benefits
Guide to Prescribed Minimum Benefits 2018 Overview All registered medical schemes in South Africa need to cover Prescribed Minimum Benefits on all the plans they offer to their members. Discovery Health
More informationPRELIMINARY REVIEWED CONDENSED CONSOLIDATED RESULTS FOR THE YEAR ENDED 31 AUGUST 2017
PRELIMINARY REVIEWED CONDENSED CONSOLIDATED RESULTS FOR THE YEAR ENDED 31 AUGUST CONTENTS 1 Commentary 2 Consolidated statement of comprehensive income Group turnover up 10.9% 3 Consolidated statement
More informationReferred to Committee on Commerce, Labor and Energy. SUMMARY Revises provisions relating to policies of health insurance.
S.B. 0 SENATE BILL NO. 0 SENATORS HARDY, SMITH, ROBERSON, BROWER, FARLEY; FORD, GOICOECHEA, GUSTAVSON, HARRIS, KIECKHEFER AND LIPPARELLI MARCH, 0 JOINT SPONSORS: ASSEMBLYMEN OSCARSON AND TITUS Referred
More informationMedicines and Allied Substances Control (Import and Export of Medicines) Regulations, 2008
Statutory Instrument 57 of 2008. [CAP. 15:03 Medicines and Allied Substances Control (Import and Export of Medicines) Regulations, 2008 ARRANGEMENT OF SECTIONS Section 1. Title. 2. Interpretation. 3. Application.
More informationVersion Control. Version Section Date Requested by Actioned by. 1.0 Revised
Policy for Joint Working with the Pharmaceutical Industry, Commercial Sponsorship & Primary Care Prescribing Rebate Schemes for Fareham and Gosport CCG and South Eastern Hampshire CCG Version 1.0 Version
More informationRe: CMS-1502-P (Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule for Calendar Year 2006)
BY ELECTRONIC DELIVERY Mark McClellan, Administrator Centers for Medicare and Medicaid Services Department of Health and Human Services Room 445-G Hubert H. Humphrey Building 200 Independence Avenue, S.W.
More informationChapter 8 Section 9.1
Other Services Chapter 8 Section 9.1 Issue Date: August 2002 Authority: 32 CFR 199.2(b), 32 CFR 199.4(b)(2)(vi), (b)(3)(iii), (b)(5)(v), (d)(3)(vi), (e)(11)(i), 32 CFR 199.5(d)(12); 32 CFR 199.17, and
More informationProtecting the Health of New Brunswickers
Pharmasave Drugs Atlantic Ltd. is pleased to provide this submission as part of the consultation process for the New Brunswick government s Fair Drug Prices for New Brunswickers. The New Brunswick government
More information713 Montreal Road POLICIES AND PROCEDURES Ottawa, Ontario K1K 0T No. FIN 015
TITLE: SIGNING AUTHORITY EFFECTIVE: DATE LAST REVIEWED: JANUARY 1988 MARCH 2011 CATEGORY: ADMINISTRATION FINANCE OTHER REFERENCES: ISSUED BY: GENERAL MANAGEMENT APPROVED BY (DATE): Board of Directors (17/03/2011)
More informationCARDINAL HEALTH REPORTS SECOND QUARTER RESULTS, REVISES EPS OUTLOOK
7000 Cardinal Place Dublin,OH 43017 www.cardinalhealth.com Contacts: Media: Jim Mazzola (614) 757-3690 jim.mazzola@cardinalhealth.com FOR IMMEDIATE RELEASE Investors: Bob Reflogal (614) 757-7542 bob.reflogal@cardinalhealth.com
More informationWhite Paper: Formulary Development at Express Scripts
White Paper: Formulary Development at Express Scripts Express Scripts works with health-benefit plan sponsors and individual members of health plans to provide affordable access to clinically sound, high-quality
More informationTOPS MARKETS, LLC NOTICE OF PRIVACY PRACTICES
TOPS MARKETS, LLC NOTICE OF PRIVACY PRACTICES Effective Date: September 23, 2013 THIS NOTICE DESCRIBES HOW MEDICAL/HEALTH INFORMATION ABOUT YOU MAY BE USED AND DISCLOSED AND HOW YOU CAN GET ACCESS TO THIS
More informationFrequently Asked Questions (FAQs) About the LIPITOR Savings Program*
Frequently Asked Questions (FAQs) About the LIPITOR Savings Program* *Terms and Conditions apply. Please see page 10 for details. You may pay less by receiving the generic. Below are some FAQs about the
More informationPublic Employees Benefits Program Legislative Session Bill Tracking Updated: 3/27/2017
Public Employees Benefits Program Legislative Session Bill Tracking Updated: 3/27/2017 Bill Number & Description Impact to PEBP & Bill Status AB249 (BDR 38-858) Requires the State Plan for Medicaid and
More informationCLICKS GROUP LIMITED Registration number: 1996/000645/06 Share code: CLS ISIN: ZAE CUSIP: 18682W205
CLICKS GROUP LIMITED Registration number: 1996/000645/06 Share code: CLS ISIN: ZAE000134854 CUSIP: 18682W205 INTERIM CONDENSED CONSOLIDATED RESULTS FOR THE SIX MONTHS ENDED 28 FEBRUARY 2017 Group turnover
More informationThe Canadian Pharmacists Association Response to Proposed Regulation Changes under the Drug Interchangeability and Dispensing Fee Act (DIDFA)
Helen Stevenson Executive Officer of Ontario Public Drug Programs and Assistant Deputy Minister Ministry of Health and Long-Term Care 80 Grosvenor Street, 9 th Floor Hepburn Block, Queen s Park Toronto,
More informationWales Patient Access Scheme: Process Guidance
Wales Patient Access Scheme: Process Guidance July 2012 (Updated August 2016) This guidance document has been prepared by the Patient Access Scheme Wales Group, with support from the All Wales Therapeutics
More informationCHAPTER 8 Section 9.1, pages 1 through 7 Section 9.1, pages 1 through 7. CHAPTER 10 Section 7.1, pages 1 and 2 Section 7.
CHANGE 20 6010.60-M MAY 3, 2018 REMOVE PAGE(S) INSERT PAGE(S) CHAPTER 8 Section 9.1, pages 1 through 7 Section 9.1, pages 1 through 7 CHAPTER 10 Section 7.1, pages 1 and 2 Section 7.1, pages 1 and 2 2
More informationInside: Critical information about your company s prescription drug benefit.
Inside: Critical information about your company s prescription drug benefit. Questions Company Benefits Managers Must Ask Their PBM It pays to make an informed decision harmacy Benefit Managers, often
More informationMARKET DEFINITION FOR FINANCING OF HEALTHCARE. 18 November 2016
MARKET DEFINITION FOR FINANCING OF HEALTHCARE 18 November 2016 CONTENTS CONTENTS... ii ABBREVIATIONS... iii INTRODUCTION... 1 MEDICAL SCHEMES... 2 Product market... 2 Key provisions of the Medical Scheme
More informationRe: CMS 2238 FC (Final Rule: Medicaid Program; Prescription Drugs)
January 2, 2008 Reference No.: FASC08001 Kerry Weems Acting Administrator, Centers for Medicare and Medicaid Services Department of Health and Human Services Room 445-G Hubert H. Humphrey Building 200
More informationThe Chairperson Portfolio Committee on Safety and Security Parliament of the Republic of South Africa P O Box 15 Cape Town 8000
28 February 2008 The Chairperson Portfolio Committee on Safety and Security Parliament of the Republic of South Africa P O Box 15 Cape Town 8000 Attention: Ms M M Sotyu, ANC MP Dear Ms Sotyu WRITTEN SUBMISSIONS
More informationREGULATORY ISSUES IMPACTING SUPPLY CHAIN
REGULATORY ISSUES IMPACTING SUPPLY CHAIN Michael Nachman Associate General Counsel John W. Jones, Jr. Partner Allan A. Thoen Partner April 27, 2017 2017 In House Counsel Conference Presenters: John W.
More informationCompetition Commission of Mauritius Guidelines: GENERAL PROVISIONS
CCM 7 Competition Commission of Mauritius Guidelines: GENERAL PROVISIONS November 2009 Competition Commission of Mauritius 2009 Guidelines General provisions 2 1. Introduction... 3 Guidelines... 3 Guidelines
More informationCOMPETITION COMMITTEE ANNUAL REPORT ON COMPETITION POLICY DEVELOPMENTS IN GREECE
COMPETITION COMMITTEE ANNUAL REPORT ON COMPETITION POLICY DEVELOPMENTS IN GREECE 2003 1 TABLE OF CONTENTS I. Changes to competition laws and policies, proposed or adopted...3 II. III. Enforcement of competition
More information2.2 Basic Aspects of Distributorship Agreements under UK Law and Court Practice
2. DISTRIBUTION 2.1 Definition A distributor buys goods from a supplier or manufacturer and resells them to his customers. In contrast to the agency model, there is no contract of sale between the supplier
More informationCHAPTER 58-29E PHARMACY BENEFITS MANAGEMENT
CHAPTER 58-29E PHARMACY BENEFITS MANAGEMENT 58-29E-1. Definition of terms. Terms used in this chapter mean: (1) "Covered entity," a nonprofit hospital or medical service corporation, health insurer, health
More informationNational Pharmaceutical Sector Form of Mongolia
National Pharmaceutical Sector Form of Mongolia Date: 12 August, 2004 Population: 2 476 644 Daily wage of lowest paid government worker 2292.9 Rate of exchange (commercial buy rate) to US dollars on the
More informationCORPORATE COUNSEL UPDATE SESSIONS QUARTER 1/2018 OUTLINE
CORPORATE COUNSEL UPDATE SESSIONS QUARTER 1/2018 Please join our CCASA CEO, Alison Lee and subject matter experts for an interactive update session where the topics set out in the below mentioned outline
More informationCompliance and Fraud, Waste, and Abuse Awareness Training. First Tier, Downstream, and Related Entities
Compliance and Fraud, Waste, and Abuse Awareness Training First Tier, Downstream, and Related Entities 1 Course Outline Overview Purpose of training Effective Compliance program Definition of Fraud, Waste,
More informationOPERATING POLICIES AND PROCEDURES OF THE PHARMACEUTICAL MANAGEMENT AGENCY ( PHARMAC ) Third Edition
OPERATING POLICIES AND PROCEDURES OF THE PHARMACEUTICAL MANAGEMENT AGENCY ( PHARMAC ) Third Edition January 2006 M1-7-9 #96112 1. INTRODUCTION 1.1 PHARMAC s Objective PHARMAC s principal objective is to
More informationRE: Comment on CMS-9937-P ( Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2017: Proposed Rule )
December 21, 2015 Centers for Medicare and Medicaid Services Department of Health and Human Services Hubert H. Humphrey Building, Room 445-G 200 Independence Avenue, SW Washington, D.C. 20201 RE: Comment
More informationJOINT NOTICE OF PRIVACY PRACTICES AND NOTICE OF ORGANIZED HEALTH CARE ARRANGEMENT
Effective Date: January 1, 2013 THIS NOTICE DESCRIBES HOW MEDICAL INFORMATION ABOUT YOU MAY BE USED AND DISCLOSED AND HOW YOU CAN GET ACCESS TO THIS INFORMATION. PLEASE REVIEW IT CAREFULLY. If you have
More informationSigma Pharmaceuticals Limited
Investor Relations Contact: Gary Woodford Corporate Affairs Manager Gary.Woodford@signet.com.au Phone: 03 9215 9632 Mobile: 0417 399 204 Mark Hooper CEO and Managing Director Gary Woodford Corporate Affairs
More informationAugust 4, The Honorable Charles Rangel, Chairman Committee on Ways and Means United States House of Representatives Washington, D.C.
August 4, 2009 The Honorable Charles Rangel, Chairman Committee on Ways and Means United States House of Representatives Washington, D.C. 20515 The Honorable Henry A. Waxman, Chairman Committee on Energy
More informationcompetitiontribunal COMPETITION TRIBUNAL REPUBLIC OF SOUTH AFRICA Premium Brand Distributors (Pty) Ltd A Ndoni(Tribunal Member)
SAFLII Note: Certain personal/private details of parties or witnesses have been redacted from this document in compliance with the law and SAFLII Policy competitiontribunal COMPETITION TRIBUNAL REPUBLIC
More informationProcedure for Unplanned Temporary Suspension of Services (Pharmacy)
Item 6.4 Procedure for Unplanned Temporary Suspension of Services (Pharmacy) Page 1 DOCUMENT STATUS: Version 1 DOCUMENT RATIFIED BY: Pharmaceutical Services Regulations Committee DATE ISSUED: October 2016
More informationFAIRFAX PHARMACEUTICAL WHOLESALER INC NEW CUSTOMER APPLICATION
FAIRFAX PHARMACEUTICAL WHOLESALER INC NEW CUSTOMER APPLICATION PLEASE PRINT OR TYPE SECTION A- GENERAL INFORMATION Business/trade name: Business/trade address: SECTION B- FINANCIAL INFORMATION -Type of
More information3. Prescription Drug Plan Options
3. Prescription Drug Plan Options Overview Electric Boat retirees and spouses have two plan levels for their prescription drug needs in 2018 that can be combined with any of the medical plan alternatives.
More informationAugust 11, Submitted electronically via Regulations.gov
August 11, 2017 Submitted electronically via Regulations.gov Centers for Medicare & Medicaid Services Department of Health and Human Services Attention: CMS-1678-P PO Box 8013 Baltimore, MD 21244-1850
More informationPolicy for the review, acceptance and monitoring of rebate schemes offered by the pharmaceutical industry
Policy for the review, acceptance and monitoring of rebate schemes offered by the pharmaceutical industry Version: Version 6 Ratified by: Date Ratified: 25 January 2018 ame & Title of originator/author(s):
More informationNew revenue guidance Implementation in the pharmaceutical and life sciences sector
No. US2017-20 September 06, 2017 What s inside: Overview... 1 Scope... 2 Step 1: Identify the contract. 2 Step 2: Identify performance obligations.. 4 Step 3: Determine transaction price.7 Step 4: Allocate
More informationSenate Substitute for HOUSE BILL No. 2026
Senate Substitute for HOUSE BILL No. 2026 AN ACT concerning the Kansas program of medical assistance; process and contract requirements; claims appeals. Be it enacted by the Legislature of the State of
More informationGAMING AND LIQUOR REGULATION
Province of Alberta GAMING AND LIQUOR ACT GAMING AND LIQUOR REGULATION Alberta Regulation 143/1996 With amendments up to and including Alberta Regulation 151/2017 Office Consolidation Published by Alberta
More information11 September Ref: 9/167. Sir David Tweedie Chairman International Accounting Standards Board 30 Cannon Street London EC4M 6XH United Kingdom
11 September 2009 Ref: 9/167 Sir David Tweedie Chairman International Accounting Standards Board 30 Cannon Street London EC4M 6XH United Kingdom Dear Sir David The International Association of Insurance
More informationConsultation report: amendments to rules
Consultation report: amendments to rules The GPhC (Registration) Rules 2010 The GPhC (Fitness to Practise and Disqualification etc.) Rules 2010, and The GPhC (Statutory Committees and their Advisers) Rules
More informationRE: Mercer Professional Dispensing Fee and Actual Acquisition Cost Analysis for Medi- Cal-Pharmacy Survey Report
February 8, 2017 Harry Hendrix, Chief Pharmacy Benefits Division Department of Health Care Services PO Box 997413 MS: 2000 Sacramento, CA 95899 RE: Mercer Professional Dispensing Fee and Actual Acquisition
More informationDefinitions.
term used in this chapter is not intended to impose any duty whatsoever upon King County or any of its officers or employees, for whom the implementation or enforcement of this chapter shall be discretionary
More informationUHY ECA TAX NEWSLETTER CORPORATE INCOME TAX An independent member of UHY International
UHY ECA TAX NEWSLETTER CORPORATE INCOME TAX 06.03.2018 An independent member of UHY International TABLE OF CONTENTS 1. Limitation in calculating to tax deductible costs 3 2. Limitation in debt financing
More informationEVERYTHING IS ONLINE. Newsletter Medical Benefit Fund
Medical Benefit Fund Newsletter 2018 EVERYTHING IS ONLINE Because it s safe and convenient, we send emails, connect with people through social media, work and even bank online. To make your life easier,
More informationChapter 8 Section 9.1
Other Services Chapter 8 Section 9.1 Issue Date: August 2002 Authority: 32 CFR 199.2(b), 32 CFR 199.4(b)(2)(vi), (b)(3)(iii), (b)(5)(v), (d)(3)(vi), (e)(11)(i), 32 CFR 199.5(d)(12); 32 CFR 199.17, and
More informationALLIANCE DOUBLE PLUS VITAL ESSENTIAL FIRST CHOICE NETWORK CHOICE
HOSPITAL ACCOMMODATION INCLUDING CONFINEMENTS SUBJECT TO PRE-AUTHORISATION ATTENDING DOCTORS AND SPECIALISTS CONSULTATIONS MEDICAL AND SURGICAL PROCEDURES INCLUDING CONFINEMENTS AUXILIARY HEALTHCARE IN
More informationState of Blockchain Adoption on the Pharmaceutical Supply Chain Industry Study
State of Blockchain Adoption on the Pharmaceutical Supply Chain Industry Study Executive Summary October 2017 The Industry Challenge Pharmaceutical manufacturers, in collaboration with their trusted partners,
More informationRecommendations for improving the medicinal product pricing process
Recommendations for improving the medicinal product pricing process Zagreb, June 2018 Contents Introduction... 3 The Current Situation in the Republic of Croatia... 4 Time Frames for Issuing Decisions...
More informationSOUTH AFRICAN HEALTHCARE INDUSTRY LANDSCAPE REPORT COMPILED: AUGUST 2018
SOUTH AFRICAN HEALTHCARE INDUSTRY LANDSCAPE REPORT COMPILED: AUGUST 2018 COMPANY OVERVIEW Insight Survey is a South African B2B market research company with more than 10 years experience, focusing on business-to-business
More informationCCG Policy on Primary Care Rebate Schemes (PCRS)
CCG Policy on Primary Care Rebate Schemes (PCRS) 1. Introduction A number of manufacturers have established rebate schemes for drugs used in primary care. Their motive for this could be speculated on for
More informationGENERAL INFORMATION INDEX
INDEX INDEX... 3 GENERAL... 4 1. SCOPE & APPLICATION OF THE SCOTTISH DRUG TARIFF... 4 2. FREQUENCY OF PUBLICATION... 5 3. DETAILS OF AMENDMENTS SINCE LAST PUBLISHED EDITION... 5 4. STANDARDS OF QUALITY
More information2. KEY NEW CHANGES INTRODUCED BY CHAPTER IV
May, 2012 ROYAL DECREE-LAW 16/2012, OF APRIL 20, 2012, ON URGENT MEASURES TO GUARANTEE THE SUSTAINABILITY OF THE NATIONAL HEALTH SYSTEM AND IMPROVE THE QUALITY AND SAFETY OF ITS SERVICES 1. INTRODUCTION
More informationCherokee Nation Businesses, LLC. Request for Proposal. For Pharmacy Audit
Cherokee Nation Businesses, LLC Request for Proposal For Pharmacy Audit Purpose & Objectives Cherokee Nation Businesses, LLC ( CNB ) is seeking responses from qualified vendors to perform an audit of the
More informationHouse Bill 2387 Ordered by the House April 27 Including House Amendments dated April 27
th OREGON LEGISLATIVE ASSEMBLY--0 Regular Session A-Engrossed House Bill Ordered by the House April Including House Amendments dated April Introduced and printed pursuant to House Rule.00. Presession filed
More informationDEVELOPMENTS IN THE PRESCRIPTION DRUG MARKET: OVERSIGHT. Before the Full House Committee on Oversight and Government Reform.
Statement for the record: DEVELOPMENTS IN THE PRESCRIPTION DRUG MARKET: OVERSIGHT Before the Full House Committee on Oversight and Government Reform February 4, 2016 David A. Balto Law Offices of David
More informationSANOFI-AVENTIS, SANOFI-SYNTHELABO INC., AND BRISTOL-MYERS SQUIBB SANOFI PHARMACEUTICALS HOLDING PARTNERSHIP, APOTEX INC. AND APOTEX CORP.
UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK SANOFI-AVENTIS, SANOFI-SYNTHELABO INC., AND BRISTOL-MYERS SQUIBB SANOFI PHARMACEUTICALS HOLDING PARTNERSHIP, Plaintiffs, Q2-CV-2255 (SHS) APOTEX
More informationFor personal use only
ASX RELEASE AusCann Strengthens Key Partnerships in March Quarter Highlights Australia AusCann welcomed the Australian Government s decision to allow cannabinoid medicines to be exported AusCann has entered
More informationD I S C O V E R Y H E A L TH A L L A B O U T M E D X P R E S S, H I V D S P A N D P E R F O R M A N C E B A S E D R E M U N E R A T I O N F O R P H A
2019 D I S C O V E R Y H E A L TH A L L A B O U T M E D X P R E S S, H I V D S P A N D P E R F O R M A N C E B A S E D R E M U N E R A T I O N F O R P H A R M A C I E S Contents Overview The medical scheme
More informationPRESENTATION OUTLINE. Review of the period Financial results Trading performance Outlook Questions
PRESENTATION OUTLINE Review of the period Financial results Trading performance Outlook Questions 2 REVIEW OF THE PERIOD DAVID KNEALE REVIEW OF THE PERIOD Strong health & beauty sales performance Increased
More informationEnglish - Or. English Directorate for Financial and Enterprise Affairs COMPETITION COMMITTEE
Unclassified DAF/COMP/AR(2015)26 DAF/COMP/AR(2015)26 Unclassified Organisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development 04-Jun-2015 English
More informationOpportunities and Challenges for Public sector Medical Insurance Schemes in a Private Sector Ms B Mfenyana 06 October 2016 Second colloquium
Opportunities and Challenges for Public sector Medical Insurance Schemes in a Private Sector Ms B Mfenyana 06 October 2016 Second colloquium Contents Purpose GEMS Background Mandate, Mission, Vision, and
More informationAccess to Medicines in Low and Middle Income Countries: Goals and Challenges. Andreas Seiter The World Bank August 2013
Access to Medicines in Low and Middle Income Countries: Goals and Challenges Andreas Seiter The World Bank August 2013 1 The World Bank and its clients Financing (IDA, subsidized) Low-Income Countries
More informationBraeburn Patient Assistance Program Application
The provides Probuphine at no cost to patients that do not have healthcare coverage and/or adequate coverage for Probuphine. All applications are reviewed on a case-by-case basis to support the Braeburn
More informationWELCOME. Your search for prescription benefit savings is now over.
CharterRx s pharmacy model is right for the times. Across Canada, CharterRx can help you achieve substantial savings while connecting your plan members to quality pharmacy services. 01 Welcome 02 Our Approach
More informationAlabama State Board of Pharmacy New Manufacturer Application
Alabama State Board of Pharmacy New Manufacturer Application Date Received Manufacturer: A person or entity, except a pharmacy, who prepares, derives, produces, researches, test, labels, or packages any
More informationExecutive Council Resolution No. (5) of Regulating. Car Parks in the Emirate of Dubai 1
Executive Council Resolution No. (5) of 2016 Regulating Car Parks in the Emirate of Dubai 1 We, Hamdan bin Mohammed bin Rashid Al Maktoum, Crown Prince of Dubai, Chairman of the Executive Council, After
More informationDrug Registration Requirements in Nigeria:
Drug Registration Requirements in Nigeria: NATIONAL AGENCY FOR FOOD AND DRUG ADMINISTRATION AND CONTROL (NAFDAC) REGISTRATION AND REGULATORY AFFAIRS DIRECTORATE National Agency for Food & Drug Administration
More informationThe Competition Commission ORDER
COMPETITION TRIBUNAL REPUBLIC OF SOUTH AFRICA Case no.: 90/CR/Dec02 In the application of: The Competition Commission Applicant And Italtile Franchising Italtile Ceramics Italtile Limited First Respondent
More information1.1 Dis-Chem Pharmacies Limited (Dis-Chem) v Mundel Gien (Pty) Ltd trading as Springbok Pharmacy (Springbok Pharmacy)
Weekly Media Statement For Immediate Release 08 March 2019 LATEST DECISIONS BY THE COMPETITION COMMISSION 1. Key decisions on mergers and acquisitions 1.1 Dis-Chem Pharmacies Limited (Dis-Chem) v Mundel
More informationSEMINAR Funders market concentration and countervailing power. 20 February 2019
SEMINAR Funders market concentration and countervailing power 20 February 2019 1 INTRODUCTION 1. This note briefly sets out the background, purpose and objectives of the HMI s seminar on funder concentration,
More informationPharmacy REGISTRATION BOARD of Western Australia (A.B.N )
Pharmacy REGISTRATION BOARD of Western Australia (A.B.N. 75 635 660 854) Mr Guy Brandon PO Box 8124 Registrar Perth BC WA 6849 Ms Sue Errington-Wood Level 4, 130 Stirling Street Assistant to the Registrar
More informationSenate Committee on Health & Welfare. January 24, 2018
Senate Committee on Health & Welfare January 24, 2018 Roll Call: Sen. Buford, Sen. Danny Carroll, Sen. Julian Carroll, Sen. Kerr, Sen. Meredith, Sen. Givens, Sen. Raque Adams, Sen. Wise, Sen. Alvarado,
More informationFaster access of patients to new medicines Revised Transparency Directive
MEMO/12/148 Brussels, 1 March 2012 Faster access of patients to new medicines Revised Transparency Directive Today the Commission adopted the Directive relating to the transparency of measures regulating
More informationApril 8, 2019 VIA Electronic Filing:
April 8, 2019 VIA Electronic Filing: http://www.regulations.gov The Honorable Alex Azar Secretary Department of Health and Human Services 200 Independence Avenue SW, Room 600E Washington, D.C. 20201 Re:
More informationMedicare Prescription Drug, Improvement and Modernization Act
International Journal of Health Research and Innovation, vol. 1, no. 2, 2013, 13-18 ISSN: 2051-5057 (print version), 2051-5065 (online) Scienpress Ltd, 2013 Medicare Prescription Drug, Improvement and
More informationMain changes to the EU Vertical Block Exemption Francesca R. Turitto
Introduction On April 20, 2010 the Commission has adopted a new Block Exemption Regulation for agreements between manufacturers and distributors for the sale of products and services (VBER) and accompanying
More informationSecurityBlue HMO. Link to Specific Guidance Regarding Exceptions and Appeals
SecurityBlue HMO Conditions and Limitations Potential for Contract Termination Disenrollment Rights and Instructions Exceptions, Prior Authorization, Appeals and Grievances Out-of-Network Coverage Quality
More informationWorkers Compensation Board Pharmacy Benefit Plan
1.0 Introduction Workers Compensation Board Pharmacy Benefit Plan Options for pharmaceutical care have greatly expanded over the past several years. New pharmaceuticals and pharmaceutical treatment modalities
More informationAPPLICATION FOR REGISTRATION OF PREMISES AS A PHARMACY [SECTION 4 PHARMACY REGULATIONS 2010]
Pharmacy Registration Board of Western Australia Level 4, 130 Stirling Street, Perth WA 6000 Telephone: (08) 9328 4388 Email: pharmacyboard@hlbwa.com.au Website: www.pharmacyboardwa.com.au APPLICATION
More informationTHE GENERAL ASSEMBLY OF PENNSYLVANIA SENATE BILL INTRODUCED BY EICHELBERGER, ARGALL, RAFFERTY, VULAKOVICH AND BROWNE, MAY 18, 2018 AN ACT
PRINTER'S NO. THE GENERAL ASSEMBLY OF PENNSYLVANIA SENATE BILL No. Session of 01 INTRODUCED BY EICHELBERGER, ARGALL, RAFFERTY, VULAKOVICH AND BROWNE, MAY 1, 01 REFERRED TO BANKING AND INSURANCE, MAY 1,
More informationCOMPETITION ISSUE IN THIS 8 OCTOBER 2018 THE COMPETITION LAW RISKS OF EARLY INTEGRATION PLANNING
8 OCTOBER 2018 COMPETITION IN THIS ISSUE THE COMPETITION LAW RISKS OF EARLY In South Africa, merger implementation is prohibited until such time as competition approval is received. Between signing of
More informationPharmacy Benefit Manager Licensure and Solvency Protection Act
Pharmacy Benefit Manager Licensure and Solvency Protection Act Section 1. Title. This Act shall be known and cited as the Pharmacy Benefit Manager Licensure and Solvency Protection Act. Section 2. Purpose
More informationSubject: Revised Comments DHA Subgroup to the DoD Regulatory Reform Task Force, Review of the Existing TRICARE Regulation (DOD-2017-HA-0060)
January 22, 2018 Department of Defense Office of the Deputy Chief Management Officer Directorate of Oversight and Compliance 4800 Mark Center Drive Alexandria, VA 22350 Subject: Revised Comments DHA Subgroup
More information